Going concern
Filing comparison
Phio Pharmaceuticals Corp. disclosed substantial doubt about its ability to continue as a going concern
No substantial-doubt conclusion identified → Substantial doubt about ability to continue as a going concern
… ed to scale back or terminate its operations or seek to merge with or to be acquired by another company. The Company has limited cash resources, has reported recurring losses from operations since inception, has negative operating cash flows and has not yet generated product revenues. As of September 30, 2026, the Company had cash and cash equivalents of approximately $10.6 million. These factors raise substantial doubt regarding the Company's ability to continue as a going concern. Based on the Company's current operating plan and existing cash resources, management believes the Company…
Evidence
- Blank check
- No
- Comparable
- Yes
- Current state
- substantial_doubt
- Current state label
- Substantial doubt about ability to continue as a going concern
- Direction
- escalated
- Located in
- filing body
- Prior filed
- 2026-08-06
- Prior form
- 10-Q
- Prior state
- none
- Prior state label
- No substantial-doubt conclusion identified
- Source
- ASC 205-40 going-concern note comparison
- Why
- Disclosure about the company's ability to continue as a going concern changed compared with its previous report.